Physician profile
Jonae Perrin
NPI 1538611686
$5,475.28
in general payments reported to CMS, 2019-2025
42 companies · $1,612 in 2025
The $1,612 reported for 2025 was more than what 88% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $246 · 2022: $656 · 2023: $1,688 · 2024: $1,273 · 2025: $1,612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,280 · Education: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,280.18 |
| Education | $293.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $426.60 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Abbvie INC. | $411.48 | 2022-2025 | |
| Janssen Biotech, INC. | $328.56 | 2022-2025 | Darzalex, Imbruvica, Talvey |
| Seagen INC. | $305.94 | 2021-2023 | Adcetris, Padcev, Tukysa |
| Novartis Pharmaceuticals Corporation | $279.59 | 2022-2025 | |
| Daiichi Sankyo INC. | $272.01 | 2021-2025 | Enhertu, Injectafer |
| Puma Biotechnology, INC. | $230.51 | 2022-2025 | |
| Pfizer INC. | $228.87 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $209.88 | 2021-2025 | Lynparza, Imfinzi |
| Glaxosmithkline, LLC. | $205.88 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Lilly USA, LLC | $172.85 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Stemline Therapeutics INC. | $164.63 | 2023-2025 | Orserdu, Elzonris |
| Genentech USA, INC. | $158.65 | 2022-2025 | Phesgo, Polivy, Perjeta |
| Astellas Pharma US INC | $147.64 | 2021-2024 | Padcev |
| Genzyme Corporation | $146.07 | 2021-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $142.62 | 2022-2024 | Sir-Spheres Microspheres |
| Myriad Genetic Laboratories, INC. | $128.90 | 2025 | Myrisk |
| Eisai INC. | $128.82 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.25 | 2021-2025 | |
| Pharmacosmos Therapeutics INC. | $126.36 | 2023-2024 | Monoferric |
| Celgene Corporation | $115.98 | 2022-2025 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $107.67 | 2023-2024 | Ninlaro, Fruzaqla |
| Karyopharm Therapeutics INC. | $105.49 | 2022-2024 | Xpovio |
| Array Biopharma INC | $95.63 | 2021-2025 | Braftovi, Mektovi, Tukysa |
| Gilead Sciences, INC. | $92.34 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $75.49 | 2022-2023 | Opdivo |
| Dendreon Pharmaceuticals LLC | $69.30 | 2023 | Provenge |
| Deciphera Pharmaceuticals INC. | $54.45 | 2021-2023 | Qinlock |
| Incyte Corporation | $46.21 | 2023-2025 | Zynyz, Monjuvi, Jakafi |
| Blueprint Medicines Corporation | $45.04 | 2022-2023 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $44.13 | 2022-2023 | Tavalisse, Rezlidhia |
| Beigene USA, INC. | $39.07 | 2023 | Brukinsa |
| Beone Medicines USA, INC. | $35.75 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $29.02 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.83 | 2023 | Gilotrif |
| Caris Mpi, INC. | $25.99 | 2025 | Mi Cancer Seek |
| Alexion Pharmaceuticals, INC. | $25.00 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $22.58 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $21.43 | 2021 | |
| Cti Biopharma Corp. | $19.01 | 2023 | Vonjo |
| Agios Pharmaceuticals, INC. | $17.98 | 2023 | Pyrukynd |
| Sobi, INC | $15.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonae Perrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.